Learn
- Cancer Types
- Issues Affecting Cancer Patients
- Asbestos and mesothelioma
- Blood clots and cancer
- Bone metastases
- Caregivers
- Chemo-induced nausea and vomiting (CINV)
- Clinical Trials
- Drug approval in Canada
- Drug pricing policy in Canada
- Drug safety in Canada
- Financial cost of cancer
- Genetic testing
- Febrile Neutropenia
- HPV and cancer
- Canadian organizations mark the first annual international HPV awareness day: Give love, not HPV
- HPV vaccine expanded to include ‘at-risk’ boys
- Key points for policy-makers and health professionals
- WHO Information on Human papillomavirus (HPV) and cervical cancer
- Human Papillomavirus and Related Cancers in Canada, Fact Sheet 2010
- Reframing the debate
- WHO/ICO Information Centre on Human Papilloma Virus (HPV) and Cervical Cancer
- Insurance and cancer
- LGBTQ+ issues
- Lymphedema
- Medical Cannabis
- Information on Medical Cannabis
- Part One: Why Cannabis Works
- Part Two: Medical Conditions & Products
- Part Three: Accessing Medical Cannabis
- Part Four: Medical Cannabis Myths & Facts
- PDQ Cancer Information Summaries
- Medical Cannabis Infographics
- Medicinal cannabis: Used throughout the ages for medicinal, therapeutic and religious purposes
- Cannabinoids: The chemical components of cannabis
- Potential therapeutic uses of medical cannabis
- Medical cannabis strains
- Cannabis contamination
- Want to learn more about the science of medical cannabis?
- Webinars & Slideshows
- Glossary of terms
- Medical Cannabis “How To”
- Medical Cannabis in the Media
- Patient Stories
- Health Canada Reports Increasing Use Of Cannabis And Cannabis Vaporization
- Canadian Cancer Survivor Network Submission : Task Force on Marijuana Legalization and Regulation
- A Framework for the Legalization and Regulation of Cannabis in Canada
- Information on Medical Cannabis
- Tumour Agnostic Treatments and Companion Diagnostics
- Mental Wellness
- New treatments
- ALECENSARO® (alectinib) approved by Health Canada for first-line treatment of ALK-positive lung cancer
- AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer
- First and Only Immuno-Oncology Treatment, Imfinzi® (durvalumab), for Stage III, Unresectable Non-Small Cell Lung Cancer Now Approved in Canada
- Health Canada Approves ERLEADA™* (apalutamide tablets), the First Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer
- Health Canada Approves GAZYVA® for Previously Untreated Advanced Follicular Lymphoma
- Health Canada approves Ipsen’s Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)
- Health Canada approves KISQALI™ for the treatment of HR-positive and HER2-negative metastatic breast cancer in postmenopausal women in combination with letrozole as an initial endocrine-based therapy
- Health Canada approves PERJETA® (pertuzumab) for the treatment of HER2-positive early breast cancer after surgery
- Health Canada Approves Tagrisso® (osimertinib) as First-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer
- Health Canada approves TECENTRIQ® (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer
- Health Canada Approves XTANDI® (enzalutamide) – the First and Only Oral Treatment for Men with Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
- Lynparza® (olaparib) Receives New Indication for BRCA-Mutated Metastatic Breast Cancer
- Lynparza® (olaparib) tablets receive approval as maintenance therapy treatment for ovarian cancer regardless of BRCA status
- Novartis receives Health Canada approval for the combination therapy of Tafinlar® (dabrafenib) plus Mekinist® (trametinib) for adjuvant treatment of patients with BRAF V600 mutation melanoma(i)
- Only Immuno-Oncology Combination Therapy Approved by Health Canada as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
- Health Canada Approves RITUXAN® Subcutaneous Formulation for Canadians with Chronic Lymphocytic Leukemia
- Health Canada Approves New Indication for ZYTIGA®* (abiraterone acetate), Broadening its Use for Treatment of Newly Diagnosed Metastatic Prostate Cancer
- Taiho Pharma Canada, Inc. announces Health Canada approval of LONSURF® (trifluridine and tipiracil tablets) for metastatic colorectal cancer
- Tagrisso® (osimertinib) receives full Health Canada approval for targeted treatment of non-small cell lung cancer
- Quebec and New Brunswick Become First Provinces to Provide Public Funding of IBRANCE™ for the First-Line Treatment of Metastatic Breast Cancer
- Palliative Care
- Prevention
- Research resources
- Wait times in Canada
- Issues Affecting Cancer Survivors
- Survivorship Issues
- Health Data Should Follow Patients
- Anorexia
- Brain Fog
- Cardiovascular Changes
- Deconditioning
- Diabetes
- Disfigurement and Amputation
- Fatigue
- Function and Mobility
- Hair Loss (Alopecia)
- Impotence
- Urinary Incontinence
- Infertility
- Lymphedema
- Mood disorders
- Bone Loss
- Ostomy
- Pain
- Post-Traumatic Stress Disorder (PTSD)
- Secondary Malignancies and Recurrence
- Swallowing and Speech
- Work Productivity
- Personal Experiences When Dealing With Cancer
- Cancer Rehabilitation
- Living Healthy
- Canadian Organizations
- USA Organizations
- Survivorship Issues
- Cancer Centres
- Medicare
- Cancer Months